Advisory Board Member

Job Description

ABOUT LUMAEGIS \n

Lumaegis is developing a faster, simpler way for healthcare providers to sterilize medical and dental instruments.

Its flagship product, RadBox™, is designed to sterilize instruments at the point of care in under six minutes — without water, steam, or chemical sterilants.

Today, many sterilization processes can take significantly longer, require bulky equipment, or depend on outsourced services. These constraints can reduce efficiency, increase operating costs, and limit clinical capacity.

RadBox is designed to provide a faster, more efficient alternative.

Potential benefits include:

\n
• Faster instrument turnaround
\n
• Improved patient throughput
\n
• Reduced reliance on outsourced sterilization
\n
• Lower instrument inventory requirements
\n
• Zero water use and significantly reduced power consumption
\n
• Greater operational flexibility across healthcare settings
\n

Behind this simple workflow is Lumaegis' patented dual-modality sterilization technology, designed for regulated healthcare environments.

Lumaegis is approaching one of the most important stages in its development.

Recent milestones include:

\n
• FDA De Novo pathway established, with the latest submission, Supplement 5, formally acknowledged by the FDA
\n
• GLP microbiology testing protocol finalized ahead of FDA-required validation
\n
• Multiple commercial Letters of Intent signed for deployment of RadBox™ systems following FDA clearance
\n
• Demonstrated a portable, battery-operated system to the Medical Future Capability Directorate, US Army Futures Command…generated extreme interest.
\n
• Patent protection progressing across the United States and Europe
\n
• Acceptance for a podium presentation at the 2026 International Ultraviolet Association (IUVA) Americas Conference
\n
• Strategic discussions underway with Singapore's Economic Development Board investment arm (EDBI) regarding potential investment and Asia-Pacific expansion support
\n

The company is targeting FDA marketing clearance in early 2027, subject to completion of the remaining regulatory milestones.

Rather than building a concept, Lumaegis is now preparing for commercial launch.

Lumaegis is expanding its Advisory Board to include a select group of experienced leaders who can provide strategic insight as the company enters its next phase of growth.

Members are expected to bring experience, perspective and valuable networks rather than operational involvement.

Areas where advisors may contribute include:

\n
• Commercial strategy
\n
• Healthcare and clinical operations
\n
• Medical device commercialisation
\n
• Regulatory and reimbursement strategy
\n
• Distribution and channel partnerships
\n
• Strategic introductions
\n
• International expansion
\n
• Corporate growth
\n

Engagement is flexible and strategic, with periodic interaction alongside the executive leadership team.

We welcome applications from experienced individuals including:

\n
• Former CEOs and founders
\n
• Healthcare executives
\n
• Medical device leaders
\n
• Hospital executives
\n
• Dental service organisation leaders
\n
• Healthcare operators
\n
• Investors with healthcare expertise
\n
• Commercial leaders within regulated industries
\n
• Board members and non-executive directors
\n

The strongest candidates are typically individuals who have built, scaled, invested in, or advised high-growth companies operating in regulated markets.

Many companies begin recruiting advisors before they have demonstrated meaningful commercial progress.

Lumaegis is doing so at a point where multiple milestones are already in place.

The company has:

\n
• A defined FDA regulatory pathway
\n
• Regulatory progress continuing toward clearance
\n
• Initial commercial customer commitments
\n
• International scientific recognition
\n
• Strategic expansion discussions in Asia-Pacific
\n
• A clear roadmap toward market launch
\n

The Advisory Board is being expanded to support this transition from regulatory execution into commercial growth.

This Advisory Board is designed for individuals who believe strategic contribution and ownership should be aligned.

Participation is equity-based rather than cash-compensated.

Members have the opportunity to contribute experience, relationships and strategic guidance while participating alongside the company's long-term growth.

Successful applicants typically have experience in one or more of the following:

\n
• Healthcare
\n
• Medical devices
\n
• Dental
\n
• Clinical operations
\n
• Hospital administration
\n
• Healthcare technology
\n
• Infection prevention
\n
• Commercialisation
\n
• Corporate strategy
\n
• Venture investing
\n
• Private equity
\n
• Scaling regulated businesses
\n